Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.54 |
| ▸ | CNR2 | P34972 | 4/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.51 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17682006 | 1.00 | CNR1 (0.54) | CNR1CNR2AHRTNNC1LMNA | |
| SCHEMBL2005564 | 1.00 | CNR1 (0.54) | CNR1CNR2AHRTNNC1LMNA | |
| SCHEMBL28162321 | 1.00 | CNR1 (0.54) | CNR1CNR2AHRTNNC1LMNA | |
| SCHEMBL15688437 | 1.00 | CNR1 (0.54) | CNR1CNR2AHRTNNC1LMNA | |
| SCHEMBL15688436 | 1.00 | CNR1 (0.54) | CNR1CNR2AHRTNNC1LMNA | |
| SCHEMBL19452377 | 1.00 | CNR1 (0.54) | CNR1CNR2AHRTNNC1LMNA | |
| SCHEMBL2005561 | 1.00 | CNR1 (0.54) | CNR1CNR2AHRTNNC1LMNA | |
| SCHEMBL6434844 | 0.98 | AHR (0.53) | CNR1CNR2AHRLMNATP53 | |
| SCHEMBL6435102 | 0.98 | AHR (0.53) | CNR1CNR2AHRLMNATP53 | |
| SCHEMBL6434839 | 0.98 | AHR (0.53) | CNR1CNR2AHRLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348283-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348283-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | TACR1, CYSLTR1, HRH3 | CNR1 23/4885CNR2 51/4885AHR 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.